You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Gene-modified cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid and Hematological Malignancies Trial in United States (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, KITE-585)

Enrolling by invitation
  • Solid and Hematological Malignancies
  • Axicabtagene Ciloleucel
  • Brexucabtagene Autoleucel (KTE-X19)
  • Duarte, California
  • +7 more
Jun 29, 2022

AIDS-related Lymphoma, HIV Trial in Hamburg (PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC))

Terminated
  • AIDS-related Lymphoma
  • HIV Infections
  • PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)
  • Hamburg, Germany
    University Medical Center Hamburg-Eppendorf
Sep 4, 2022

ß-thalassemia Trial (BD211)

Not yet recruiting
  • β-thalassemia
  • BD211
  • (no location specified)
Mar 15, 2023

ß-thalassemia Trial in Shanghai (BD211)

Not yet recruiting
  • β-thalassemia
  • BD211
  • Shanghai, China
    Shanghai Ruijin Hospital
Mar 16, 2023

Patients Who Received Gene-Modified Cell Therapy

Enrolling by invitation
  • Long-term Follow-up
  • Gene-Modified Cell Therapy
  • Philadelphia, Pennsylvania
    Abramson Cancer Center Clinical Research Unit, University of Pen
Jul 21, 2022

HIV-1 Infections Trial in Washington (HAART, T cells)

Completed
  • HIV-1 Infections
  • Washington, District of Columbia
    Walter Reed Army Medical Center
Aug 17, 2022

Glioblastoma Trial in Birmingham (Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified

Not yet recruiting
  • Glioblastoma
  • Autologous genetically modified gamma-delta T cells
  • Allogeneic genetically modified gamma-delta T cells
  • Birmingham, Alabama
    University of Alabama at Birmingham
Dec 16, 2022

Survival of Genetically Modified White Blood Cells in

Active, not recruiting
  • HIV
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Jan 3, 2023

    Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

    Active, not recruiting
    • Leukemia
    • Acute Lymphoblastic Leukemia
    • gene-modified T cells targeted
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Feb 1, 2023

    Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)

    Active, not recruiting
    • Sickle Cell Disease
    • DREPAGLOBE drug product
    • Paris, France
      Department of Biotherapy, Necker-Enfants Malades Hospital
    Sep 26, 2022

    Neuroblastoma Trial in Houston (SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP, SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2

    Active, not recruiting
    • Neuroblastoma
    • SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
    • SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
    • Houston, Texas
      Texas Children's Hospital
    Mar 3, 2022

    Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

    Completed
    • Acute Lymphoblastic Leukemia
    • CAR-NK-CD19 Cells
    • Sanhe, Hebei, China
      Hebei Yanda Ludaopei Hospital
    Nov 24, 2022

    Mucopolysaccharidosis II Trial (Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII)

    Not yet recruiting
    • Mucopolysaccharidosis II
    • Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
    • (no location specified)
    Dec 16, 2022

    Sickle Cell Disease Trial in Los Angeles (ßAS3-FB vector transduced peripheral blood CD34+ cells)

    Recruiting
    • Sickle Cell Disease
    • βAS3-FB vector transduced peripheral blood CD34+ cells
    • Los Angeles, California
      University of California, Los Angeles (UCLA)
    Apr 9, 2022

    Hematologic Malignancy Trial in Pavia, Rome, Turin (BPX-501 T cells, rimiducid)

    Active, not recruiting
    • Hematologic Malignancy
    • Pavia, Italy
    • +2 more
    Jul 10, 2022

    Neuroblastoma Trial in Houston (Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN

    Active, not recruiting
    • Neuroblastoma
    • Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells
    • Cytoxan
    • Houston, Texas
      Texas Children's Hospital
    Mar 25, 2022

    Mucopolysaccharidosis IH Trial in Milano (Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified

    Active, not recruiting
    • Mucopolysaccharidosis IH
    • Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.
    • Milano, Italy
      Ospedale San Raffaele
    Aug 6, 2021

    Metastatic Melanoma Trial in Los Angeles (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative

    Completed
    Has Results
    • Metastatic Melanoma
    • F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
    • non-myeloablative conditioning chemotherapy
    • Los Angeles, California
      University of California Los Angeles, David Geffen School of Med
    Dec 3, 2021

    Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma Trial in United States (biological, drug, procedure)

    Active, not recruiting
    • Acute Lymphoblastic Leukemia
    • +3 more
    • BPX-501 dose 1
    • +5 more
    • Atlanta, Georgia
    • +7 more
    Jul 10, 2022

    Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer Trial in New Brunswick, Providence (anti-CEA CAR-T cells)

    Withdrawn
    • Peritoneal Carcinomatosis
    • +6 more
    • anti-CEA CAR-T cells
    • New Brunswick, New Jersey
    • +1 more
    Mar 25, 2022

    Mucopolysaccharidosis Type IIIA Trial in Manchester (Autologous CD34+ cells transduced with a lentiviral vector containing the

    Active, not recruiting
    • Mucopolysaccharidosis Type IIIA
    • Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
    • Manchester, United Kingdom
      Manchester University NHS Foundation Trust
    Jul 2, 2021

    Brain Tumor Adult Trial in Birmingham (DRI cell therapy)

    Recruiting
    • Brain Tumor Adult
    • DRI cell therapy
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Feb 1, 2022

    Multiple Myeloma Trial in Milan (Temferon)

    Terminated
    Has Results
    • Multiple Myeloma
    • Milan, Italy
      Ospedale San Raffaele
    Jan 27, 2022

    Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

    Recruiting
    • Advanced Solid Tumors
    • Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
    • Hangzhou, China
      First affiliated hospital, School of Medicine, Zhejiang Universi
    Aug 3, 2023

    Sickle Cell Disease Trial in Boston (Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA

    Recruiting
    • Sickle Cell Disease
    • Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
    • Los Angeles, California
    • +8 more
    Jan 10, 2023